Education
About Us
Working with TipRanks
Follow Us
Collplant Holdings (CLGN)
NASDAQ:CLGN
CLGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.35 - $5.48
Previous CloseN/A
Volume800.00
Average Volume (3M)194.25K
Market Cap
$17.55M
Enterprise Value$7.92M
Total Cash (Recent Filing)$11.91M
Total Debt (Recent Filing)$3.08M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Aug 21, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding12,716,014
10 Day Avg. Volume128,616
30 Day Avg. Volume194,252
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)1.28
Price to Sales (P/S)0.00
P/FCF Ratio-1.27
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue0.63
Enterprise Value/Gross Profit-5.69
Enterprise Value/Ebitda-0.14
Forecast
1Y Price Target
$11.00Price Target Upside697.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Collplant Holdings News
PremiumCompany Announcements
CollPlant Expands Collaboration with STEMCELL Technologies
PremiumCompany Announcements
CollPlant Secures European Patent for Collagen-Based Formulations
PremiumCompany Announcements
CollPlant Biotechnologies Announces $3.6 Million Securities Offering
PremiumCompany Announcements
CollPlant Biotechnologies Secures $3.6 Million in Direct OfferingBulls Say, Bears Say
Bulls Say
PartnershipsCollPlant continues to progress the clinical development of its dermal and soft-tissue filler program in collaboration with AbbVie.
Product DevelopmentEncouraging initial breast implant data shows signs of implant integration and rapid growth of native tissue, supporting potential future commercialization.
Bears Say
Financial PerformanceThe company reported total revenues of $0.25M, compared to the consensus estimate of $0.69M.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.05% Mutual Funds
11.15% Other Institutional Investors
88.80% Public Companies and
Individual Investors
CLGN FAQ
What was Collplant Holdings’s price range in the past 12 months?
Collplant Holdings lowest stock price was $1.35 and its highest was $5.48 in the past 12 months.
What is Collplant Holdings’s market cap?
Collplant Holdings’s market cap is $17.55M.
When is Collplant Holdings’s upcoming earnings report date?
Collplant Holdings’s upcoming earnings report date is Aug 21, 2025 which is in 52 days.
How were Collplant Holdings’s earnings last quarter?
Collplant Holdings released its earnings results on May 28, 2025. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.17.
Is Collplant Holdings overvalued?
According to Wall Street analysts Collplant Holdings’s price is currently Undervalued.
Does Collplant Holdings pay dividends?
Collplant Holdings does not currently pay dividends.
What is Collplant Holdings’s EPS estimate?
Collplant Holdings’s EPS estimate is -0.1.
How many shares outstanding does Collplant Holdings have?
Collplant Holdings has 12,716,014 shares outstanding.
What happened to Collplant Holdings’s price movement after its last earnings report?
Collplant Holdings reported an EPS of $0.13 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went up 76.166%.
Which hedge fund is a major shareholder of Collplant Holdings?
Currently, no hedge funds are holding shares in CLGN
Collplant Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (697.10% Upside)
$11.00 (697.10% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.40%
12-Months-Change
Fundamentals
Return on Equity
-75.27%
Trailing 12-Months
Asset Growth
-43.19%
Trailing 12-Months
Company Description
Collplant Holdings
Collplant Holdings (CLGN) is a regenerative medicine company that operates in the biotechnology sector. The company specializes in the development and commercialization of bioactive medical products for the fields of 3D bioprinting, medical aesthetics, and organ and tissue repair. Collplant's core technology is based on recombinant human collagen (rhCollagen) produced from genetically engineered tobacco plants, which serves as the foundation for their innovative products.
CLGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Despite significant advancements in preclinical programs and continued collaboration with AbbVie, the company experienced a sharp decline in annual revenue and increased net losses, presenting a mixed financial outlook.Read More>Technical Analysis
PolyPid
―
ALX Oncology Holdings
―
Spruce Biosciences
―
Aligos Therapeutics
―
Sensei Biotherapeutics
―